The selective CCR1 antagonist CCX721 has demonstrated efficacy in reducing tumor burden and osteolytic lesions in a murine model of multiple myeloma (MM) by blocking osteoclasts (49). This evidence concerns the gene CCR1 and AL amyloidosis.